Streamline the ADC Path to the Clinic with One-stop Drug Development and Critical Technology Advancements
Update: 2021-12-20
Description
In this podcast, I talked with Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how one-stop drug development organizations greatly streamline a pathway to the clinic. He also shares new technologies available to make the development of Antibody Drug Conjugates (ADCs) more efficient and effective.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
